BRIEF published on 05/19/2026 at 07:05, 9 days ago Innate Pharma at the Jefferies Global Healthcare Conference Immunotherapy Cancer Innate Pharma Therapeutic Antibodies Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 9 days ago Innate Pharma à la Conférence Jefferies Global Healthcare Immunothérapie Cancer Innate Pharma Conférence Jefferies Anticorps Thérapeutiques
BRIEF published on 05/19/2026 at 07:05, 9 days ago Innate Pharma participera à la conférence mondiale sur les soins de santé de Jefferies Biotechnologie Immunothérapie Traitement Du Cancer Innate Pharma Conférence Jefferies
BRIEF published on 05/19/2026 at 07:05, 9 days ago Innate Pharma to Attend Jefferies Global Healthcare Conference Biotechnology Cancer Treatment Immunotherapy Innate Pharma Jefferies Conference
PRESS RELEASE published on 05/19/2026 at 07:00, 9 days ago Informations privilégiées / Autres communiqués Innate Pharma participera à la conférence Jefferies Global Healthcare 2026 à New York. La société de biotechnologies développe des traitements d'immunothérapies contre le cancer Conference Cancer Innate Pharma Biotechnologies Immunothérapies
PRESS RELEASE published on 05/19/2026 at 07:00, 9 days ago Inside Information / Other news releases Innate Pharma to participate in Jefferies Global Healthcare Conference on June 2-4, 2026 in New York, United States. Developing immunotherapies for cancer patients Biotechnology Innate Pharma Jefferies Global Healthcare Conference Immunothérapies Cancer Patients
BRIEF published on 04/17/2026 at 21:05, 1 month 10 days ago Innate Pharma presents interim results from the MATISSE trial at the AACR congress Lung Cancer Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
BRIEF published on 04/17/2026 at 21:05, 1 month 10 days ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 1 month 10 days ago Innate Pharma dévoile des résultats intermédiaires prometteurs dans l'étude de phase 2 MATISSE Essais Cliniques Cancer Du Poumon Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 1 month 10 days ago Innate Pharma présente des résultats intermédiaires de l'essai MATISSE au congrès AACR Cancer Du Poumon Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
Published on 05/28/2026 at 01:15, 6 hours 42 minutes ago JM Capital II Corp. Announces Departure of President, Chief Financial Officer and Chief Financial Officer Jay Freeman
Published on 05/28/2026 at 00:55, 7 hours 2 minutes ago First Helium Closes Oversubscribed $2.6 Million Placement
Published on 05/27/2026 at 23:42, 8 hours 15 minutes ago New Horizon Aircraft Ltd. Announces Closing of $25 Million Offering of Common Shares
Published on 05/27/2026 at 23:05, 8 hours 52 minutes ago Vox Royalty Announces Annual and Special Meeting Results
Published on 05/27/2026 at 23:05, 8 hours 52 minutes ago Avino Reports Voting Results of Its 2026 Annual General Meeting
Published on 05/28/2026 at 07:30, 27 minutes ago EVN AG: Business development in the first half of 2025/26
Published on 05/28/2026 at 07:30, 27 minutes ago Ernst Russ AG Publishes Business Figures for the First Quarter of 2026
Published on 05/28/2026 at 07:30, 27 minutes ago Northern Data Group Announces CFO Move to Advisory Role
Published on 05/28/2026 at 07:30, 27 minutes ago Magirus starts 2026 with strong momentum in Q1, record high order intake; Mutares initiates preparation of exit process
Published on 05/28/2026 at 07:30, 27 minutes ago BRAIN Biotech AG reports half-year figures for fiscal year 2025/26 and confirms full year guidance
Published on 05/27/2026 at 23:00, 8 hours 57 minutes ago BIOPHYTIS MODIFIE SA LIGNE DE FINANCEMENT AVEC HEXAGON CAPITAL FUND POUR RENDRE RENOUVELABLE SA CAPACITE DE TIRAGE DE 2M€
Published on 05/27/2026 at 23:00, 8 hours 57 minutes ago BIOPHYTIS CHANGES ITS FINANCING AGREEMENT WITH HEXAGON CAPITAL FUND TO ENSURE ITS €2 MILLION FACILITY IS RENEWABLE
Published on 05/27/2026 at 20:28, 11 hours 29 minutes ago Combined Shareholders’ Meeting of May 27, 2026
Published on 05/27/2026 at 17:45, 14 hours 12 minutes ago Imerys-05-2026-communique-capital-droits-de-vote-au-30-avril-2026
